HEPA

Hepion Pharmaceuticals
HEPA

Overview Fund Activity
Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

25 hedge funds and large institutions have $3.61M invested in Hepion Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
25
Holders Change
-3
Holders Change %
-10.71%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
5
Closed
7
Calls
$97K
Puts
$8K
Net Calls
+$89K
Net Calls Change
-$45K

Top Buyers

1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$36.1K
2
VF
Virtu Financial
New York
+$22.5K
3
Envestnet Asset Management
Envestnet Asset Management
Illinois
+$14K
4
Citadel Advisors
Citadel Advisors
Florida
+$11K
5
Cetera Investment Advisers
Cetera Investment Advisers
Illinois
+$6K

Top Sellers

1
IC
Ikarian Capital
Texas
-$235K
2
BFM
Boothbay Fund Management
New York
-$26K
3
Jane Street
Jane Street
New York
-$23K
4
BlackRock
BlackRock
New York
-$11.1K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$8K
Name Holding Trade Value Shares
Change 		Shares
Change %
IC
26
Ikarian Capital
Texas
– -$235K -410 Closed
BFM
27
Boothbay Fund Management
New York
– -$26K -45 Closed
Jane Street
28
Jane Street
New York
– -$23K -40 Closed
Commonwealth Equity Services
29
Commonwealth Equity Services
Massachusetts
– -$5K -10 Closed
AWA
30
Amplius Wealth Advisors
Pennsylvania
– -$5K -10 Closed
GWM
31
Geneos Wealth Management
Colorado
– -$2K -5 Closed
CS
32
Credit Suisse
Switzerland
– -$1K -2 Closed
1
2